Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report)’s share price was down 8.6% on Friday following a dissappointing earnings announcement. The stock traded as low as $23.29 and last traded at $22.5550. 118,665 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,546,845 shares. The stock had previously closed at $24.69.
The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The business had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.
Key Headlines Impacting Nurix Therapeutics
Here are the key news stories impacting Nurix Therapeutics this week:
- Positive Sentiment: Nurix announced a global collaboration with Roche for bexobrutideg that could bring up to $2.3 billion in total payments, including a $700 million upfront payment, which is a major validation of the company’s pipeline and a meaningful source of non-dilutive capital. Article Title
- Positive Sentiment: Needham & Company LLC reaffirmed its Buy rating and set a $34 price target, implying notable upside from recent trading levels. Article Title
- Positive Sentiment: BTIG Research also reiterated a Buy rating with a $32 price target, reinforcing the view that the Roche deal and broader pipeline remain attractive to analysts. Article Title
- Neutral Sentiment: Nurix’s second-quarter results were weaker than expected, with a loss of $0.81 per share versus estimates for a $0.72 loss and revenue of $9.04 million versus $15.29 million expected, highlighting ongoing operating losses and revenue volatility. Article Title
- Neutral Sentiment: Additional coverage of the Q2 2026 earnings release echoed the same miss on EPS and revenue, which may temper enthusiasm but is partly offset by the Roche collaboration and analyst upgrades. Article Title
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on NRIX
Insider Activity at Nurix Therapeutics
In related news, insider Gwenn Hansen sold 5,394 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares in the company, valued at $624,027.20. This represents a 27.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 25,051 shares of company stock valued at $434,466. 6.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Larson Financial Group LLC grew its stake in shares of Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management bought a new stake in Nurix Therapeutics in the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics in the fourth quarter valued at about $33,000. KBC Group NV acquired a new position in Nurix Therapeutics in the first quarter valued at about $34,000. Finally, Wexford Capital LP bought a new position in Nurix Therapeutics during the third quarter worth about $41,000.
Nurix Therapeutics Stock Down 8.0%
The stock has a market cap of $2.35 billion, a P/E ratio of -7.18 and a beta of 1.80. The stock has a fifty day simple moving average of $18.31 and a 200-day simple moving average of $17.33.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Read More
- Five stocks we like better than Nurix Therapeutics
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
- Broadcom’s $30 Billion Apple Deal: This Chip Giant Is About More than Just AI
- IQM’s Nasdaq Debut Could Change the Quantum Race for D-Wave
- Buyer Beware: These 2 Stocks Charts Just Displayed a Death Cross
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
